Global trends in molecular epidemiology of HIV-1 during 2000-2007

被引:562
作者
Hemelaar, Joris [1 ]
Gouws, Eleanor [2 ]
Ghys, Peter D. [2 ]
Osmanov, Saladin [3 ]
机构
[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Womens Ctr, Oxford OX3 9DU, England
[2] UNAIDS, Epidemiol & Anal Div, Geneva, Switzerland
[3] World Hlth Org, WHO UNAIDS HIV Vaccine Initiat, Geneva, Switzerland
关键词
circulating recombinant form; HIV; molecular epidemiology; recombinant; subtype; vaccine; DISEASE PROGRESSION; DOUBLE-BLIND; SUBTYPE-A; INFECTION; VACCINE; DIVERSITY; TRANSMISSION; RECOMBINANTS; THAILAND; UGANDA;
D O I
10.1097/QAD.0b013e328342ff93
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To estimate the global and regional distribution of HIV-1 subtypes and recombinants between 2000 and 2007. Design: Country-specific HIV-1 molecular epidemiology data were combined with estimates of the number of HIV-infected people in each country. Methods: Cross-sectional HIV-1 subtyping data were collected from 65 913 samples in 109 countries between 2000 and 2007. The distribution of HIV-1 subtypes in individual countries was weighted according to the number of HIV-infected people in each country to generate estimates of regional and global HIV-1 subtype distribution for the periods 2000-2003 and 2004-2007. Results: Analysis of the global distribution of HIV-1 subtypes and recombinants in the two periods indicated a broadly stable distribution of HIV-1 subtypes worldwide with a notable increase in the proportion of circulating recombinant forms (CRFs), a decrease in unique recombinant forms (URFs) and an overall increase in recombinants. In 20042007, subtype C accounted for nearly half (48%) of all global infections, followed by subtypes A (12%) and B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) and D (2%). Subtypes F, H, J and K together cause fewer than 1% of infections worldwide. Other CRFs and URFs are each responsible for 4% of global infections, bringing the combined total of worldwide CRFs to 16% and all recombinants (CRFs along with URFs) to 20%. Conclusion: The global and regional distributions of individual subtypes and recombinants are broadly stable, although CRFs may play an increasing role in the HIV pandemic. The global diversity of HIV-1 poses a formidable challenge to HIV vaccine development. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:679 / 689
页数:11
相关论文
共 28 条
[1]  
[Anonymous], 2009, AIDS EP UPD 2009
[2]  
[Anonymous], 2008, REP GLOB AIDS EP
[3]   Is HIV-1 evolving to a less virulent form in humans? [J].
Arien, Kevin K. ;
Vanham, Guido ;
Arts, Eric J. .
NATURE REVIEWS MICROBIOLOGY, 2007, 5 (02) :141-151
[4]   HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads [J].
Baeten, Jared M. ;
Chohan, Bhavna ;
Lavreys, Ludo ;
Chohan, Vrasha ;
McClelland, R. Scott ;
Certain, Laura ;
Mandaliya, Kishorchandra ;
Jaoko, Walter ;
Overbaugh, Julie .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (08) :1177-1180
[5]   Challenges in the development of an HIV-1 vaccine [J].
Barouch, Dan H. .
NATURE, 2008, 455 (7213) :613-619
[6]   Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].
Buchbinder, Susan P. ;
Mehrotra, Devon V. ;
Duerr, Ann ;
Fitzgerald, Daniel W. ;
Mogg, Robin ;
Li, David ;
Gilbert, Peter B. ;
Lama, Javier R. ;
Marmor, Michael ;
del Rio, Carlos ;
McElrath, M. Juliana ;
Casimiro, Danilo R. ;
Gottesdiener, Keith M. ;
Chodakewitz, Jeffrey A. ;
Corey, Lawrence ;
Robertson, Michael N. .
LANCET, 2008, 372 (9653) :1881-1893
[7]   HIV vaccines: mosaic approach to virus diversity [J].
Corey, Lawrence ;
McElrath, M. Juliana .
NATURE MEDICINE, 2010, 16 (03) :268-270
[8]   AIDS - Diversity considerations in HIV-1 vaccine selection [J].
Gaschen, B ;
Taylor, J ;
Yusim, K ;
Foley, B ;
Gao, F ;
Lang, D ;
Novitsky, V ;
Haynes, B ;
Hahn, BH ;
Bhattacharya, T ;
Korber, B .
SCIENCE, 2002, 296 (5577) :2354-2360
[9]   Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy [J].
Geretti, Anna Maria ;
Harrison, Linda ;
Green, Hannah ;
Sabin, Caroline ;
Hill, Teresa ;
Fearnhill, Esther ;
Pillay, Deenan ;
Dunn, David .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (09) :1296-1305
[10]   The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection [J].
Goonetilleke, Nilu ;
Liu, Michael K. P. ;
Salazar-Gonzalez, Jesus F. ;
Ferrari, Guido ;
Giorgi, Elena ;
Ganusov, Vitaly V. ;
Keele, Brandon F. ;
Learn, Gerald H. ;
Turnbull, Emma L. ;
Salazar, Maria G. ;
Weinhold, Kent J. ;
Moore, Stephen ;
Letvin, Norman ;
Haynes, Barton F. ;
Cohen, Myron S. ;
Hraber, Peter ;
Bhattacharya, Tanmoy ;
Borrow, Persephone ;
Perelson, Alan S. ;
Hahn, Beatrice H. ;
Shaw, George M. ;
Korber, Bette T. ;
McMichael, Andrew J. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (06) :1253-1272